Please login to the form below

Not currently logged in
Email:
Password:

S-A wins award for malaria programme

Sanofi-aventis has won the 2010 Global Business Coalition Core Competence Award for its Malaria Access to Medicines programme

Sanofi-aventis (S-A) has won the 2010 Global Business Coalition Core Competence Award for the Malaria Access to Medicines programme – a campaign to combat the disease, devised in partnership with the Drugs for Neglected Diseases Initiative (DNDi).

The awards honour organisations who have shown pioneering skills and strategies in the fight against HIV/AIDS, tuberculosis and malaria.

Previous winners have included Warner Bros. Entertainment, who developed an action-based video game pilot that delivered targeted HIV prevention messages to East African youths, and the BBC World Service Trust for its mass media HIV/AIDS campaign in India.

The Malaria Access to Medicines Programme has seen S-A and not-for-profit product developers, DNDi, develop and distribute anti-malarial treatment, Coarsucam, or ASAQ (artesunate amodiaquine winthrop) in the poorest areas of sub-sharan Africa.

ASAQ is the first anti-malarial treatment to be aimed at such a patient group, in particular children.

The treatment costs less than $1 for an adult and less than $0.50 for children when distributed to non-profit organisations in the area.

More than 50 million ASAQ treatments have been distributed since 2008 when the treatment was pre-qualified by the World Health Organisation (WHO).

Commenting on the award, Global Business Coalition CEO, John Todstrom said: "The sanofi-aventis ASAQ programme has produced real results in helping to address one of the three greatest threats of our time. We congratulate them on their richly deserved success."

25th May 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics